Johnson & Johnson made the largest splash at this year’s JP Morgan Healthcare Conference, acquiring Intra-Cellular Therapies and its neuropsychiatric drug Caplyta for $14.6 billion.
On the company’s fourth-quarter earnings call Wednesday ...
↧
